To define the effect of adenosine A 1 receptor (A 1 R) on delta opioid receptor (DOR)-mediated signal transduction. Methods: CHO cells stably expressing HA-tagged A 1 R and DOR-CFP fusion protein were used. The localization of receptors was observed using confocal microscope. DOR-mediated inhibition of adenylyl cyclase was measured using cyclic AMP assay. Western blots were employed to detect the phosphorylation of Akt and the DOR. The effect of A 1 R agonist N 6 -cyclohexyladenosine (CHA) on DOR down-regulation was assessed using radioligand binding assay.
Introduction
Accumulating evidence supports an interaction between adenosine and opioids in the central nervous system and the myocardium [1] . For example, previous studies indicate an interaction between adenosine A 1 receptor (A 1 R) and delta opioid receptor (DOR) in analgesia [2] and cardioprotection [3] . Moreover, A 1 R has also been shown to be involved in the development of opioid dependence [4] . A 1 R and DOR both belong to the G protein-coupled receptor (GPCR) superfamily. Acute activation of A 1 R [5] and DOR [6] inhibit adenylyl cyclase activity via inhibitory G protein (G i ), and lead to a decrease in intracellular cAMP levels. However, upon prolonged exposure to their agonists, these receptors undergo desensitization which is indicated by the decreased ability to mediate agonistinduced inhibition of adenylyl cyclase [7] [8] [9] [10] [11] . Receptor desensitization was also measured by the activities of other downstream effectors stimulated by selective receptor agonists in various signaling pathway such as ERK1/2 and Akt/PKB [12] , which depends on not only the functional status of the receptor but also the signal transduction amplification between the receptor and the effectors [13] . In cells expressing multiple GPCRs, prolonged stimulation of these GPCRs have been shown to result in not only homologous desensitization, but sometimes also heterologous desensitization [14] [15] [16] , which refer to a process whereby the activation of one type of receptor results in the desensitization of other types of receptor. It has been reported that prolonged A 1 R agonist (-)N 6 -phenylisopropyl adenosine (PIA) treatment causes heterologous desensitization of PGE 1 receptor to inhibit lipolysis [17] , and cross desensitization has also been shown between DOR and CB 1 -cannabinoid receptors [18] , D 2 -dopaminergic receptor, and α 2 -adrenergic receptor [19] . However, it is [9, 13] , and heterologous desensitization was suggested to correlate with heterologous receptor phosphorylation [20] . DOR undergoes down-regulation after chronic selective agonist exposure, for different agonists the magnitude and time-course of receptor down-regulation varied [21] [22] [23] , nevertheless, all recent studies favor the idea that reduction of active opioid receptors from the cell surface would potentiate their desensitization.
The present study was undertaken to investigate the effect of prolonged A 1 R agonist N 6 -Cyclohexyladenosine (CHA) exposure on DOR-mediated regulation of intracellular cAMP levels and Akt phosphorylation in the CHO cell line stably co-expressing A 1 R and DOR, and to determine whether prolonged CHA exposure could cause the phosphorylation and down-regulation of DOR.
Materials and methods

Materials
Plasmid encoding N-terminal 3xHA (Hemagglutinin)-tagged human Adenosine A 1 receptor was purchased from UMR cDNA Resource Center (Rolla, MO, USA). CHA, DPDPE, DPCPX, Naloxone, and monoclonal Anti-HA-TRITC antibody were purchased from Sigma (St Louis, MO, USA). Anti-phospho-Akt1/2/3 (Ser 473) and anti-Akt1/2/3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-DOR (Ser363) antibody was purchased from Cell Signaling Technology (Beverly, MA, USA). [8- 3 H] adenine and ECL plus Western Blotting Detection Reagents were purchased from GE Healthcare (Little Chalfont, Buckinghamshire, UK).
Cell culture CHO cells were maintained in F12 medium (Gibco) with 10% fetal calf serum, and incubated in a humidified atmosphere consisting of 5% CO 2 at 37 °C. For the CHO-A 1 R-DOR cells, 0.5 mg/mL G418 was added to maintain selection.
Transfection
The plasmids containing cDNA of N-terminal 3xHA-tagged human Adenosine A 1 receptor (HA-A 1 R) were transfected into CHO cells by using Lipofectamine 2000 (Invitrogen). Cells stably expressing HA-A 1 R were selected by culture with 1.0 mg/mL G418 for two weeks, then labeled with monoclonal anti-HA-TRITC antibody, and screened by fluorescence microscope (Olympus Optical Co Ltd). Subsequently, the CHO-A 1 R cells were transfected with the plasmids containing cDNA of mouse delta opioid receptor-enhanced cyan fluorescent fusion protein (DOR-CFP). Cells stably co-expressing DOR-CFP and HA-A 1 R were screened by fluorescence microscope.
Confocal microscopy
Conforcal microscopy test was preformed as described previously [24] . Briefly, cells were seeded onto poly-D-lysine coated coverslips placed in a 24-well plate at 37 °C. Cells were washed with PBS, fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100. Cells were incubated with 2% BSA as blocking solution and with anti-HA-TRITC antibody at room temperature for 1 h, washed, and incubated with Hoechst for 15 min. Fluorescence was observed with a Leica TCS NT laser scanning confocal microscope.
Cyclic AMP assay
The levels of intracellular cAMP were measured as described [25, 26] . In brief, cells were cultured in 24-well plates, serum starved, and incubated at 37 °C for 2 h in 0.5 mL/well of fresh growth medium containing 5 μCi/mL [8- 3 H]-adenine, 0.5 mmol/L 1-methyl-3-isobutylxanthine (IBMX), and with or without 1 μmol/L CHA of indicated duration. The incubation with [8- 3 H]-adenine and different time course pretreatment of CHA always ended at the same time. After incubation and extensive washing to remove residual, cells were incubated in an Assay Mixture (10 μmol/L Forskolin, 0.5 mmol/L IBMX, dissolved in Krebs-Ringer HEPES buffer) with or without the indicated concentrations of DPDPE at 37 °C for 15 min. 50 μL of 2.2 mol/L HCl was added to terminate the reaction. The cAMP was separated by Alumina column chromatography, and radioactivity was determined by liquid scintillation counting.
Western blot analysis
Cells were seeded in 24-well plates, incubated at 37 °C for 24 h, and starved in serum free media overnight. After treated with indicated chemicals, cells were lysed immediately by RIPA extraction buffer, and boiled for 10 min. Cell extracts were subjected to 10%-SDS polyacrylamide gel electrophoresis, and transferred onto nitrocellulose membrane (Amersham Biosciences). The immunoblots were detected as described previously [24] . Membranes were blocked with 5% non-fat dried milk dissolved in PBS/0.1% Tween 20 (PBS/T) for 1 h, and incubated overnight at 4 °C with primary antibodies diluted in PBS/T containing 5% non-fat dried milk. Membranes were subjected to 4 washes with PBS/T before incubating for 1 h at room temperature with a horseradish peroxidase-conjugated secondary antibody (Calbiochem). Chemiluminescence detection was performed with ECL Plus Western Blotting Detection Reagent (GE Healthcare). Immunoblots were quantified by densitometry with Quantity One (Bio-Rad). For repeated immunoblotting, membranes were stripped in ReBlot Plus Mild Antibody Stripping Solution for 15 min (Millipore Chemicon).
Plasma membrane preparation
Cell were seeded in 100-mm diameter dishes, incubated for 24 h to 90% confluence, and treated with or without CHA (1 μmol/L) for 72 h, the reaction is terminated on the ice. Cells were detached, and collected by centrifugation. Plasma
Acta Pharmacologica Sinica npg membrane fractions were prepared with a Dounce homogenizer as descried [27] . Cells were detached by incubation with phosphate-buffered saline containing 1 mmol/L EDTA and centrifuged at 1000×g for 10 min. The cell pellet was suspended in ice-cold homogenization buffer composed of 50 mmol/L HEPES, pH 7.4, 1 mmol/L MgCl 2 , and 1 mmol/L EGTA. Cells were homogenized with 20 strokes using a glass Dounce homogenizer. After centrifugation at 40 000×g for 10 min (4 °C), pellets were resuspended in homogenization buffer, homogenized, and centrifuged again as described. This procedure was repeated twice more. The final pellets were resuspended in a 50 mmol/L Tris-HCl buffer, pH 7.4. Protein concentration was determined and aliquots were stored at -80 °C.
Radioligand binding assay
Radioligand binding assay was performed as described previously [27] . The DOR number were detected by incubating 
Statistical analysis
All statistical and curve-fitting analysis was performed by the GraphPad Prism 4.0 software (GraphPad software, San Diego, CA, USA). Data are presented as mean±SEM, except the EC 50 values which are presented as mean (95% confidence interval), from at least three separate experiments. Statistical significance was determined by unpaired t-test.
Results
Coexpression of HA-A 1 R and DOR-CFP in CHO cells In order to study the possible cross-talk in signaling transduction between the A 1 R and DOR, HA-tagged A 1 R and CFPtagged DOR were stably transfected into CHO cells. Coexpression of A 1 R and DOR was visualized by confocal microscope, and functional activity was examined by assessing the effect of selective A 1 R and DOR agonists on intracellular cAMP accumulation, because both A 1 R and DOR inhibit adenylyl cyclase activity via G i when acutely activated by their agonists, leading to reduction of intracellular cAMP levels [5, 6, 28] . As shown in Figure 1 , functional A 1 R and DOR coexpressed in the CHO cells. Confocal images showed that A 1 R and DOR co-localized on the plasma membrane of the CHO cells ( Figure  1A) . A 1 R agonist CHA (1 μmol/L) and DOR agonist DPDPE (1 μmol/L) both significantly inhibited forskolin-stimulated cAMP accumulation ( Figure 1B) .
CHA pretreatment decreased the ability of DOR agonist DPDPE to inhibit adenylyl cyclase and phosphorate (activate) Akt in the CHO-A 1 R/DOR cells To determine whether there is an interaction between the A 1 R and DOR in signal transduction, we first examined the effect of A 1 R agonist CHA pretreatment on DOR-mediated inhibition of adenylyl cyclase. Like many other GPCRs, the opioid receptors undergo phosphorylation, desensitization, internalization, and down-regulation after prolonged exposure to agonists and these receptor regulatory mechanisms may play an important role in regulation of opioid receptor function. DPDPE dose dependently inhibited forskolin stimulated cAMP accumulation with EC 50 value of 0.095 nmol/L and E max value of 83.64% ( Figure 2A , Table 1 ). Pretreatment of CHO-A1R/DOR cells with 1 μmol/L CHA for 24 h caused a right shift of the doseresponse curve (Figure 2A) , with a 4.38 fold increase in EC 50 value, while the E max showed no statistically significant differences between pretreatment with and without CHA ( Table 1) . CHA time dependently attenuated DOR-mediated inhibition of intracellular cAMP, with a t 1/2 =2.56 (2.09-3.31) h ( Figure  2B ). It indicated that pretreatment of CHO-A1R /DOR cells with A 1 R agonist led to heterologous desensitization of DORmediated inhibition of intracellular cAMP accumulation. The serine-threonine kinas Akt is one of the key downstream targets of PI3K signaling, which regulates cell growth, differentiation, survival and functions. Activation of DOR by its agonist leads to activation of PI3K/Akt signaling pathway [29] . To further confirm the desensitization of DORmediated signaling by A 1 R agonist CHA treatment, we examined the effect of CHA pretreatment on DPDPE-stimulated phosphorylation (activation) of Akt. Both CHA and DPDPE induced a robust but transient phosphorylation of Akt1/2/3 (Ser473, Figure 3A) . However, pAkt induced by CHA appears to be more persistent than that induced by DPDPE. As anticipated, pretreatment of cells with 1 μmol/L CHA for 1 h abolished the phosphorylation of Akt by DPDPE ( Figure 3B,  3C ). Taken together, these results clearly indicate that CHA pretreatment led to the heterologous desensitization of DORmediated signaling. 
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The EC 50 and E max value were obtained from the dose-response curve of DOR mediated inhibition of cAMP accumulation described in Figure  2A . After CHA pretreatment, the EC 50 of inhibition cAMP accumulation by DPDPE increased significantly, while the E max showed no statistically significant differences between pretreatment with and without CHA. EC 50 values are presented as mean (95% confidence interval), while E max values are represented as means±SEM, from three independent experiments performed in duplicate. CHA heterologously phosphorylated DOR and this effect was inhibited by A 1 R antagonist DPCPX but not by opioid receptor antagonist naloxone It is generally considered that the molecular mechanisms underlying G protein coupled receptors (GPCRs) desensitization included receptor phosphorylation and subsequent downregulation. Phosphorylation of Ser363 residue in the C-terminal tail of DOR has been shown to be important for agonistmediated homologous desensitization and internaliza tion [9, 30] . Our recent study demonstrated that DPDPE treatment induced rapid phosphorylation of Ser363 residue in the C-terminal tail of DOR and led to desensitization of the DOR [24] . To determine the mechanisms by which CHA pretreatment resulted in heterologous desensitization of DOR-mediated signaling, we examined the effect of CHA pretreatment on the phosphorylation of DOR. By Western blot analysis with a specific phospho-DOR (Ser363) primary antibody, we found Figure 4A ). We also found that the heterologous phosphorylation of DOR by 1 μmol/L CHA was completely blocked by concomitant treatment of the cells with a selective A 1 R antagonist DPCPX (100 μmol/L) but not opioid receptor antagonist naloxone (100 μmol/L) ( Figure 4B ), suggesting that the DOR and A 1 R may undergo cross-talk at receptor levels.
Chronic CHA pretreatment caused no significant down-regulation of the DOR Changes in receptor number or affinity provide an attractive mechanism to explain the loss of receptor responsiveness that is characteristic of desensitization. Previous studies showed that A 1 R agonist (R)-PIA induced a time-dependent reduction in cell surface adenosine A1 receptor radioligand binding sites, which reached a maximum at 48-72 h [31, 32] . To examine whether heterologous desensitization of the DOR by CHA was attributed to receptor down-regulation, saturation binding was used to assess receptor affinity (K d ) and receptor density (B max ) of DOR in plasma membranes prepared from cells pretreated with or without 1 μmol/L CHA for 72 h. Saturation curves of DOR ( Figure 5A ) and the Scatchard analysis of the saturation binding ( Figure 5B ) were present in Figure 5 , which showed no significant change of receptor numbers and affinity after chronic CHA exposure. There were no statistically significant differences in B max (Control, 2.587±0.359 pmol/mg protein; CHA pretreated, 2.454±0.390 pmol/mg protein) or K d (Control, 0.7269±0.0543 nmol/L; CHA pretreated, 0.7372±0.0916 nmol/ L), indicating that chronic CHA treatment failed to induce DOR down-regulation. This result suggests that heterologous desensitization of DOR-mediated signaling by CHA may not be due to the down-regulation of the DOR.
Discussion
Previous studies revealed a tight cross-talk between A 1 R and DOR. The present study demonstrated that prolonged exposure to A 1 R agonist CHA resulted in heterologous desensitization of DOR-mediated inhibition of intracellular cAMP accumulation and Akt phosphorylation in CHO-A 1 R/DOR cells. The heterologous desensitization of DOR-mediated inhibition of intracellular cAMP accumulation was partly, with a significant increase in EC 50 but no change in B max, whereas heterologous desensitization of DOR-mediate Akt signaling was almost completely, and preceded the desensitization of cAMP signaling, suggesting that the heterologous desensitization of DOR was specific in different signaling pathway. These results support that there is a tight cross-talk between A 1 R and DOR in the regulation their functions. Desensitization of opioid receptors and its link with opiate tolerance and dependence have been extensively investigated [33, 34] . Furthermore, cross tolerance between A 1 R and µ opioid receptor has been observed previously [35] . Thus, the heterologous desensitization may be a possible mechanism underlying opiate tolerance in vivo.
Previous study showed that DOR underwent phosphory- 
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Acta Pharmacologica Sinica npg lation and down-regulation after prolonged agonist exposure, which contributed to the homologous desensitization of DOR [24] . In this study, prolonged CHA exposure caused heterologous phosphorylation of DOR, which was blocked by DPCPX but not naloxone, indicating that DOR was phosphorylated by CHA via A 1 R activation. Although receptor phosphorylation independent of homologous [11] and heterologous [36] desensitization was demonstrated, there is strong evidence showing the causal relationship between desensitization and receptor phosphorylation [9, 13] . Thus, we speculate that CHA-induced phosphorylation of the DOR may be a potential mechanism underlying the heterologous desensitization of DOR-mediated signaling by CHA treatment. However, further work is needed to confirm this speculation.
Receptor down-regulation is known to be subsequent to receptor phosphorylation and internalization. After internalization, receptor could either recycle from endosomes to the plasma membrane and reduce desensitization, or degraded in lysosomes to decrease functional receptors on cell membrane and enhance desensitization [23] . In this study, prolonged CHA treatment did not induce DOR down-regulation, which suggests that receptor down-regulation is not a necessary consequence of phosphorylation. As prolonged CHA exposure caused no down-regulation of DOR, it seems that receptor down-regulation may not be the mechanism of heterologous desensitization of DOR by A 1 R agonist CHA.
In conclusion, we found that prolonged A 1 R stimulation resulted in heterologous desensitization of DOR-mediated inhibition of intracellular cAMP levels and Akt phosphorylation. We also found that activation of A 1 R by its agonist induced heterologous phosphorylation but not down-regulation of the DOR. The findings of the present study suggest that receptor phosphorylation, but not down-regulation, may contribute to the heterologous desensitization of DORmediated signaling by CHA. These results may shed some light on the molecular mechanism of interaction between A 1 R and DOR. Since desensitization of opioid receptor signaling can also result from changes at post-receptor components such as G-proteins, effectors, or their regulators, further work is needed to elucidate the mechanisms by which CHA induces heterologous desensitization of the DOR signaling.
